ArticleBlood cancer journal2018

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Arnon P Kater et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.